Evaluation of human serum S100B protein as a prognostic factor in nonmetastatic breast cancer patients

IF 0.4 Q4 ONCOLOGY

Breast Cancer Management Pub Date : 2018-11-01 DOI:10.2217/BMT-2018-0008

F. H. Shandiz, K. Ghaffarzadegan, Saeed Jahani Fariman, M. Jannati, S. Elyasi, A. Mohammadpour

引用次数: 1

Abstract

Aim: The aim of this study was the evaluation of S100B prognostic role in nonmetastatic breast cancer patients, excluding confounding factors. Patients & method: 79 breast cancer patients, who fulfilled inclusion and exclusion criteria, were enrolled in the study. Before any adjuvant chemotherapy or surgery, the serum level of S100B was determined. All patients were followed up for 5 years, particularly regarding cancer recurrence and patients’ survival. Results: 42% of the patients experienced no recurrence after 5 years and cumulative risk of recurrence was 0.86. There was no significant correlation between serum level of protein S100B and recurrence rate in 5 years (p = 0.59). Conclusion: According to the results, the serum levels of S100B protein may have no prognostic role in nonmetastatic breast cancer.

查看原文本刊更多论文

人血清S100B蛋白作为非转移性乳腺癌患者预后因素的评价

目的:本研究的目的是评估S100B在排除混杂因素的非转移性乳腺癌患者中的预后作用。患者和方法:79例符合纳入和排除标准的乳腺癌患者入组研究。在任何辅助化疗或手术前，测定血清S100B水平。所有患者随访5年，重点关注癌症复发和患者生存情况。结果:42%的患者5年后无复发，累计复发风险为0.86。血清S100B蛋白水平与5年复发率无显著相关性(p = 0.59)。结论:血清S100B蛋白水平对非转移性乳腺癌患者的预后无影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast Cancer Management ONCOLOGY-

CiteScore

0.60

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Breast Cancer Management (ISSN: 1758-1923) addresses key issues in disease management by exploring the best patient-centered clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in the clinic. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Breast Cancer Management provides oncologists and other health professionals with the latest findings and opinions on reducing the burden of this widespread disease. Recent research findings and advances clinical practice in the field are reported and analyzed by international experts. The journal presents this information in clear, accessible formats. All articles are subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal’s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3. Coverage includes: Diagnosis and imaging, Surgical approaches, Radiotherapy, Systemic therapies, Cancer clinical trials, Genetic aspects of disease, Personalized medicine, Translational research and biomarker studies, Management of psychological distress, Epidemiological studies, Pharmacoeconomics, Evidence-based treatment guidelines.